News

MHRA Launches 2026–2030 Women’s Health Programme After Finding Pregnant Women in 1.1% of Trial Applications

The UK medicines regulator launched a 2026–2030 programme on 16 November to tackle evidence gaps on how medicines and devices affect women.

MHRA Launches 2026–2030 Women’s Health Programme After Finding Pregnant Women in 1.1% of Trial Applications

The UK Medicines and Healthcare products Regulatory Agency (MHRA) launched a Women’s Health Programme for 2026 to 2030 on 16 November 2026. The programme is meant to tackle gaps in the evidence on how medicines and medical devices affect women.

The agency announced it at the inaugural DIA-MHRA Global Summit in London, which runs 16 to 17 November as part of London Life Sciences Week. The MHRA and the Drug Information Association co-host the summit. The programme was published on GOV.UK the same day.

What the MHRA Found in Trial Applications

The launch follows an MHRA analysis of 4,616 UK clinical trial applications submitted between 2019 and 2023. Pregnant women appeared in 1.1% of those applications, and breastfeeding women in 0.6%.

The agency notes that women make up 51% of the population. It describes women as underrepresented in the clinical research that informs the medicines and devices they use.

The MHRA says historic underrepresentation in clinical research has limited the evidence available on medicines and medical devices during pregnancy and across reproductive health. It also says women continue to face gaps in research and treatment across a range of health conditions.

The programme also refers to the UK FemTech sector, which the MHRA says has an annual turnover of nearly £300 million.

The Trial Figures
The MHRA reviewed 4,616 UK clinical trial applications from 2019 to 2023. Pregnant women were included in 1.1% and breastfeeding women in 0.6%.

What the Programme Sets Out to Do

The programme sits under the MHRA’s Strategy to 2030, within the priority of proactive regulation to address evidence gaps and reduce inequalities. It is the agency’s regulatory contribution to the renewed Women’s Health Strategy for England. The MHRA says related work covers Scotland, Wales and Northern Ireland.

According to News Anyway, the Department of Health and Social Care published the renewed strategy in April 2026. The same report says it replaced a 2022 strategy that was withdrawn in May 2026, and that the MHRA’s 2030 strategy had committed to launching the work, which it calls a Women’s Health Plan, in the year the 2030 strategy was published.

The MHRA’s stated aims are to bring together patients, researchers, healthcare professionals and industry, and to work with researchers and innovators early to build better evidence on how the benefits and risks of medicines may differ for women. It also wants promising technologies to reach patients sooner while keeping standards of safety, quality and effectiveness.

National Health Executive says women’s health specialists have highlighted the challenges created by limited clinical data, particularly in areas such as pregnancy, menopause and reproductive health. It also reports that the MHRA believes improved research and better data will support safer prescribing decisions.

How Patients Shaped the Programme

The MHRA says patients helped shape the programme, including through its Patient and Public Community and a focus group run by the Patients Association.

The full 32-page programme document is on GOV.UK. The MHRA presents the programme as the first part of a wider health inequalities initiative under its 2030 strategy.

Pregnant women appeared in 1.1% of those applications, and breastfeeding women in 0.6%.

What Officials and Industry Said

Women’s Health Minister Baroness Gillian Merron said “for too long, women’s health has been overlooked.” She said women have been underrepresented in the research behind the medicines and devices they rely on, and that the government intends to change that. She described the programme as a welcome step alongside the renewed Women’s Health Strategy.

MHRA Chief Executive Lawrence Tallon said better evidence can help the agency understand where important differences exist, and can support healthcare better tailored to women’s needs. He described closing gaps in understanding how the risks and benefits of medicines and medical devices differ for women as both a challenge and an opportunity.

Naho Yamazaki, Deputy Director of Policy and Partnerships at the Health Research Authority, welcomed the programme. She pointed to joint MHRA and Health Research Authority guidance on an Inclusion and Diversity Plan, which researchers can use from the earliest design stages.

Michelle Riddalls, chief executive of PAGB, the consumer healthcare association, said better evidence can help women make more informed choices. She said it could also widen access to treatment through reclassification of medicines. She cited the reclassification of low-dose estradiol vaginal products and estriol cream as having transformed access to hormone replacement therapy for thousands of women.

What Happens Next

The MHRA will hold an introductory webinar on Wednesday 9 December 2026, from 11am to 12pm. It is intended to introduce the programme and outline plans to strengthen evidence and support women’s health innovation. Interest can be registered via Eventbrite.

The programme covers 2026 to 2030.

The MHRA is an executive agency of the Department of Health and Social Care. Media enquiries go to its news centre.

Read next